{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:51:18Z","timestamp":1788371478460,"version":"build-2803163510"},"reference-count":37,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>Raltitrexed (RTX) is a thymidylate synthase inhibitor with large pharmacokinetics (PK) variability that can be administered in case of 5\u2010fluorouracil (5FU) intolerance or dihydropyrimidine dehydrogenase deficiency. While it is a more potent thymidylate synthase inhibitor than 5FU, RTX failed to replace this drug for colorectal cancer patients, mainly due to its toxicity at the recommended dose of 3 mg\/m<jats:sup>2<\/jats:sup> every 3 weeks. However, every 2 weeks administration at 2 mg\/m<jats:sup>2<\/jats:sup> demonstrated a favourable toxicity profile.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>We performed a randomized crossover comparative population PK study between every 2 weeks TOMOX (RTX 2 mg\/m<jats:sup>2<\/jats:sup>) and every 3 weeks TOMOX (RTX 3 mg\/m<jats:sup>2<\/jats:sup>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A three\u2010compartment model and a proportional error model best describe the data. Creatinine clearance and sex, but not body surface area (BSA), were covariates of RTX clearance leading to decrease of its interindividual variability of 28%. Weight and body surface area were covariates of central and peripheral volumes of distribution, respectively, leading to decreases of interindividual variability of 34.6% and 100%, respectively. In contrast to the dose, AUC was a good predictor of liver toxicity (<jats:italic>P<\/jats:italic> = 0.006, OR = 3.91, 95%CI = [1.48\u201010.34]). Using covariates to compute individual clearance and a threshold AUC (1.639, determined in this study), a covariates\u2010based dose was calculated, leading to less variability in AUC than observed with the actual BSA\u2010based or fixed doses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These results advocate for the use of creatinine clearance and sex to determine the RTX dose instead of BSA.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.14519","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T06:19:47Z","timestamp":1597299587000},"page":"1327-1337","source":"Crossref","is-referenced-by-count":7,"title":["Exposure\u2010response analysis of Raltitrexed assessing liver toxicity"],"prefix":"10.1111","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1379-858X","authenticated-orcid":false,"given":"Bernard","family":"Royer","sequence":"first","affiliation":[{"name":"Laboratoire de Pharmacologie Clinique et Toxicologie CHU Besan\u00e7on  Besan\u00e7on F\u201025000 France"},{"name":"INSERM, EFS BFC Universit\u00e9 Bourgogne Franche\u2010Comt\u00e9  UMR1098, Interactions H\u00f4te\u2010Greffon\u2010Tumeur\/Ing\u00e9nierie Cellulaire et G\u00e9nique Besan\u00e7on F\u201025000 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3132-7730","authenticated-orcid":false,"given":"Antonin","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Service Pharmacie Centre Georges\u2010Fran\u00e7ois Leclerc  Dijon F\u201021000 France"},{"name":"Universit\u00e9 Bourgogne Franche\u2010Comt\u00e9  INSERM U1231 Dijon F\u201021000 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Service d'Oncologie m\u00e9dicale  CHU Besan\u00e7on Besan\u00e7on F\u201025000 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010Justine","family":"Paillard","sequence":"additional","affiliation":[{"name":"Service d'Oncologie m\u00e9dicale  CHU Besan\u00e7on Besan\u00e7on F\u201025000 France"},{"name":"Unit\u00e9 de m\u00e9thodologie et de qualit\u00e9 de vie en canc\u00e9rologie CHU Besan\u00e7on  Besan\u00e7on F\u201025000 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Jary","sequence":"additional","affiliation":[{"name":"INSERM, EFS BFC Universit\u00e9 Bourgogne Franche\u2010Comt\u00e9  UMR1098, Interactions H\u00f4te\u2010Greffon\u2010Tumeur\/Ing\u00e9nierie Cellulaire et G\u00e9nique Besan\u00e7on F\u201025000 France"},{"name":"Service d'Oncologie m\u00e9dicale  CHU Besan\u00e7on Besan\u00e7on F\u201025000 France"},{"name":"INSERM CIC\u20101431 , CHU Besan\u00e7on  Besan\u00e7on F\u201025000 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Demarchi","sequence":"additional","affiliation":[{"name":"Service d'Oncologie m\u00e9dicale  CHU Besan\u00e7on Besan\u00e7on F\u201025000 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewi","family":"Vernerey","sequence":"additional","affiliation":[{"name":"INSERM, EFS BFC Universit\u00e9 Bourgogne Franche\u2010Comt\u00e9  UMR1098, Interactions H\u00f4te\u2010Greffon\u2010Tumeur\/Ing\u00e9nierie Cellulaire et G\u00e9nique Besan\u00e7on F\u201025000 France"},{"name":"Unit\u00e9 de m\u00e9thodologie et de qualit\u00e9 de vie en canc\u00e9rologie CHU Besan\u00e7on  Besan\u00e7on F\u201025000 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Henriques","sequence":"additional","affiliation":[{"name":"INSERM, EFS BFC Universit\u00e9 Bourgogne Franche\u2010Comt\u00e9  UMR1098, Interactions H\u00f4te\u2010Greffon\u2010Tumeur\/Ing\u00e9nierie Cellulaire et G\u00e9nique Besan\u00e7on F\u201025000 France"},{"name":"Unit\u00e9 de m\u00e9thodologie et de qualit\u00e9 de vie en canc\u00e9rologie CHU Besan\u00e7on  Besan\u00e7on F\u201025000 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Jacquin","sequence":"additional","affiliation":[{"name":"INSERM CIC\u20101431 , CHU Besan\u00e7on  Besan\u00e7on F\u201025000 France"},{"name":"Canc\u00e9rop\u00f4le Grand Est  France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Borg","sequence":"additional","affiliation":[{"name":"INSERM, EFS BFC Universit\u00e9 Bourgogne Franche\u2010Comt\u00e9  UMR1098, Interactions H\u00f4te\u2010Greffon\u2010Tumeur\/Ing\u00e9nierie Cellulaire et G\u00e9nique Besan\u00e7on F\u201025000 France"},{"name":"Service d'Oncologie m\u00e9dicale  CHU Besan\u00e7on Besan\u00e7on F\u201025000 France"},{"name":"INSERM CIC\u20101431 , CHU Besan\u00e7on  Besan\u00e7on F\u201025000 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Kim","sequence":"additional","affiliation":[{"name":"INSERM, EFS BFC Universit\u00e9 Bourgogne Franche\u2010Comt\u00e9  UMR1098, Interactions H\u00f4te\u2010Greffon\u2010Tumeur\/Ing\u00e9nierie Cellulaire et G\u00e9nique Besan\u00e7on F\u201025000 France"},{"name":"Service d'Oncologie m\u00e9dicale  CHU Besan\u00e7on Besan\u00e7on F\u201025000 France"},{"name":"INSERM CIC\u20101431 , CHU Besan\u00e7on  Besan\u00e7on F\u201025000 France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,9,4]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(95)00166-G"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.07.002"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010800"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08514-8"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.9.2943"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000094357"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000133"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602860"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/07357900701518388"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl953"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2003.02050.x"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-2-2"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2017.06.021"},{"key":"e_1_2_10_15_1","volume-title":"NONMEM User's Guides. (1989\u20102009)","author":"Beal S"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2010.04.018"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.14"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1024467714170"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-011-9255-z"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2007.12.002"},{"key":"e_1_2_10_21_1","first-page":"5579","article-title":"ICI D1694, a Quinazoline Antifolate thymidylate synthase inhibitor that is a potent inhibitor of LI 210 tumor cell growth in vitro and in vivo: a new agent for clinical study","volume":"51","author":"Jackman AL","year":"1991","journal-title":"Cancer Res"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0157"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010546"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.8.2799-2807.2004"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04498.x"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200847030-00006"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03298.x"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200039060-00004"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.652"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1233606"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.2863"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-8-924"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.24.1883"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(02)00151-X"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-005-0036-1"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.357"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2017.05.056"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050787"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.14519","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14519","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.14519","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14519","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T11:47:45Z","timestamp":1693655265000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.14519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,4]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1111\/bcp.14519"],"URL":"https:\/\/doi.org\/10.1111\/bcp.14519","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,4]]}}}